We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
Read MoreHide Full Article
Key Takeaways
ABBV's Venclexta plus azacitidine missed the survival goal in the phase III VERONA study for MDS.
The trial showed a hazard ratio of 0.908, indicating no significant survival benefit over control.
ABBV continues building its oncology pipeline, now including five marketed therapies and late-stage assets.
AbbVie (ABBV - Free Report) announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study evaluated a combination therapy involving its blockbuster cancer drug Venclexta (venetoclax) in newly diagnosed patients with higher-risk myelodysplastic syndrome (MDS).
The VERONA study tested the combination of Venclexta and azacitidine against azacitidine plus placebo. Results showed a hazard ratio (HR) of 0.908, indicating that AbbVie’s combination therapy did not significantly reduce the risk of death compared to the control group. Full data from this study will be presented at a future medical meeting.
This is not the first clinical setback for Venclexta. In 2023, AbbVie reported that a late-stage study evaluating Venclexta plus dexamethasone in certain multiple myeloma patients also failed to meet its primary endpoint of progression-free survival (PFS).
Per AbbVie, these setbacks do not impact any currently approved indication for the drug.
ABBV Stock Performance
Year to date, shares of AbbVie have risen 8% compared with the industry‘s 3% growth.
Image Source: Zacks Investment Research
Venclexta – A Key Driver of ABBV’s Top Line
Venclexta is approved by the FDA to treat two blood disorders, namely chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). The drug is also approved for similar indications in Europe, where it is marketed under the brand name Venclyxto.
In the first three months of 2025, the drug added sales worth $665 million to AbbVie’s top line, up 12% year over year. This growth is being driven by strong demand for both CLL and AML indications.
The drug is marketed in partnership with Roche (RHHBY - Free Report) . While both AbbVie and Roche are responsible for marketing the drug in the United States, AbbVie holds the right to commercialize the drug outside the country.
ABBV’s Growing Oncology Portfolio
Despite the VERONA setback, AbbVie has continued to diversify and expand its oncology pipeline. Initially anchored by Imbruvica and Venclexta, the company has expanded its offerings to include Epkinly, Elahere and, most recently, Emrelis, bringing the total to five oncology therapies.
ABBV also has an exciting and diverse pipeline of promising new therapies in both blood cancers and solid tumors. Notably, etentamig (formerly ABBV-383), a BCMA x CD3 bispecific antibody, is currently being evaluated in a late-stage study for relapsed/refractory multiple myeloma.
The company is also developing another c-Met targeting ADC called Temab-A (formerly ABBV-400). This drug is being evaluated in a late-stage study for metastatic colorectal cancer and mid-stage development for gastroesophageal cancer.
In the past 60 days, loss estimates for Immunocore’s 2025 have improved from $1.50 to 86 cents per share. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained around 12% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
In the past 60 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $4.66 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $5.02 to $1.99. AGEN stock has soared nearly 88% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
Key Takeaways
AbbVie (ABBV - Free Report) announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study evaluated a combination therapy involving its blockbuster cancer drug Venclexta (venetoclax) in newly diagnosed patients with higher-risk myelodysplastic syndrome (MDS).
The VERONA study tested the combination of Venclexta and azacitidine against azacitidine plus placebo. Results showed a hazard ratio (HR) of 0.908, indicating that AbbVie’s combination therapy did not significantly reduce the risk of death compared to the control group. Full data from this study will be presented at a future medical meeting.
This is not the first clinical setback for Venclexta. In 2023, AbbVie reported that a late-stage study evaluating Venclexta plus dexamethasone in certain multiple myeloma patients also failed to meet its primary endpoint of progression-free survival (PFS).
Per AbbVie, these setbacks do not impact any currently approved indication for the drug.
ABBV Stock Performance
Year to date, shares of AbbVie have risen 8% compared with the industry‘s 3% growth.
Image Source: Zacks Investment Research
Venclexta – A Key Driver of ABBV’s Top Line
Venclexta is approved by the FDA to treat two blood disorders, namely chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). The drug is also approved for similar indications in Europe, where it is marketed under the brand name Venclyxto.
In the first three months of 2025, the drug added sales worth $665 million to AbbVie’s top line, up 12% year over year. This growth is being driven by strong demand for both CLL and AML indications.
The drug is marketed in partnership with Roche (RHHBY - Free Report) . While both AbbVie and Roche are responsible for marketing the drug in the United States, AbbVie holds the right to commercialize the drug outside the country.
ABBV’s Growing Oncology Portfolio
Despite the VERONA setback, AbbVie has continued to diversify and expand its oncology pipeline. Initially anchored by Imbruvica and Venclexta, the company has expanded its offerings to include Epkinly, Elahere and, most recently, Emrelis, bringing the total to five oncology therapies.
ABBV also has an exciting and diverse pipeline of promising new therapies in both blood cancers and solid tumors. Notably, etentamig (formerly ABBV-383), a BCMA x CD3 bispecific antibody, is currently being evaluated in a late-stage study for relapsed/refractory multiple myeloma.
The company is also developing another c-Met targeting ADC called Temab-A (formerly ABBV-400). This drug is being evaluated in a late-stage study for metastatic colorectal cancer and mid-stage development for gastroesophageal cancer.
ABBV’s Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold).
AbbVie Inc. Price
AbbVie Inc. price | AbbVie Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Immunocore (IMCR - Free Report) and Agenus (AGEN - Free Report) . While IMCR sports a Zacks Rank #1 (Strong Buy) at present, AGEN carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, loss estimates for Immunocore’s 2025 have improved from $1.50 to 86 cents per share. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained around 12% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
In the past 60 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $4.66 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $5.02 to $1.99. AGEN stock has soared nearly 88% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.